Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Oct. 31, 2018
Oct. 31, 2017
Revenue $ 1,112,500 $ 362,500
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses 768,410 104,556
Amortization of patents 325,296 325,296
Research and development expenses (including non-cash share based compensation expenses of $4,596,866 and $288,187, respectively) 6,813,043 1,597,550
General and administrative expenses (including non-cash share based compensation expenses of $4,298,748 and $1,388,585, respectively) 6,911,830 4,410,682
Impairment in carrying amount of patent assets (Note 2) 582,979
Total operating costs and expenses 15,401,558 6,438,084
Loss from operations (14,289,058) (6,075,584)
Gain on extinguishment of patent acquisition obligation (Note 4) 1,547,608
Interest expense (Notes 4 and 5) (500,455)
Interest income 45,974 19,440
Loss before income taxes (14,243,084) (5,008,991)
Provision for income taxes (Note 7)
Net loss (14,243,084) (5,008,991)
Less: Net loss attributable to noncontrolling interest (247,059)
Net loss attributable to common shareholders before deemed dividend (13,996,025) (5,008,991)
Deemed dividend to preferred stockholder (Note 5) (2,008,775)
Net loss attributable to common stockholders $ (13,996,025) $ (7,017,766)
Net loss per share:    
Basic and diluted (in Dollars per share) $ (0.79) $ (0.58)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 17,624,335 12,197,340